Arcutis Biotherapeutics, Inc. - Common stock (NQ:ARQT)

25.16 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Arcutis Biotherapeutics, Inc. - Common stock

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Arcutis Announces Positive Results from INTEGUMENT-PED Pivotal Phase 3 Trial of Roflumilast Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5

September 19, 2023

From Arcutis Biotherapeutics, Inc.

Via GlobeNewswire

Arcutis Submits Roflumilast Cream 0.15% Supplemental New Drug Application to the FDA for the Treatment of Atopic Dermatitis in Adults and Children Ages 6 Years and Older

September 12, 2023

From Arcutis Biotherapeutics, Inc.

Via GlobeNewswire

Why Shares of Arcutis Biotherapeutics Fell This Week ↗

September 07, 2023

The company released phase 3 trial results for an atopic dermatitis cream.

Via The Motley Fool

7 Analysts Have This to Say About Arcutis Biotherapeutics ↗

August 10, 2023

Via Benzinga

8 Analysts Have This to Say About Arcutis Biotherapeutics ↗

July 18, 2023

Via Benzinga

Analyst Ratings for Arcutis Biotherapeutics ↗

June 28, 2023

Via Benzinga

US Stocks Mostly Higher; RH Posts Upbeat Earnings ↗

September 08, 2023

U.S. stocks traded mostly higher this morning, with the Nasdaq Composite gaining around 60 points on Friday. Following the market opening Friday, the Dow traded down 0.03% to 34,491.98 while the NASDAQ...

Via Benzinga

Topics Stocks

Arcutis Announces Positive Long-Term Results of Roflumilast Cream 0.15% Showing Durable and Improved Efficacy Over Time and Favorable Safety Profile in Treatment of Mild to Moderate Atopic Dermatitis (AD)

September 07, 2023

From Arcutis Biotherapeutics, Inc.

Via GlobeNewswire

Arcutis to Present at Upcoming Investor Conference

September 05, 2023

From Arcutis Biotherapeutics, Inc.

Via GlobeNewswire

Analyst Expectations for Arcutis Biotherapeutics's Future ↗

June 12, 2023

Via Benzinga

The Latest Analyst Ratings for Arcutis Biotherapeutics ↗

May 17, 2023

Via Benzinga

Arcutis Biotherapeutics: Q1 Earnings Insights ↗

May 09, 2023

Via Benzinga

3 Biotech Stocks Due for a Massive Short Squeeze ↗

August 31, 2023

These are the biotech short squeeze candidates to buy and hold for a massive rally of up to 100% in the coming quarters.

Via InvestorPlace

Arcutis Biotherapeutics Publishes Annual Environmental, Social, and Governance (ESG) Report

August 31, 2023

From Arcutis Biotherapeutics, Inc.

Via GlobeNewswire

Arcutis Launches First Television Ad for ZORYVE® (Roflumilast) Cream 0.3%

August 29, 2023

From Arcutis Biotherapeutics, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Monday's Intraday Session ↗

August 21, 2023

Via Benzinga

Why Super League Gaming Are Trading Lower By Around 46%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

August 21, 2023

Gainers China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) shares jumped 120% to $0.33.

Via Benzinga

Week In Review: Hengrui Out-Licenses Novel Anti-Inflammatory To One Bio In $1 Billion Deal ↗

August 19, 2023

Jiangsu Hengrui Pharma out-licensed global rights (ex-China) for a novel anti-inflammatory to One Bio of Florida in a $1 billion deal. One Bio will make an $21.5 million payment upfront along with a...

Via Talk Markets

Arcutis Appoints Interim Chief Financial Officer (CFO)

August 18, 2023

Former and First Arcutis CFO, John Smither, Appointed Interim

From Arcutis Biotherapeutics, Inc.

Via GlobeNewswire

Arcutis and Huadong Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Greater China and Southeast Asia

August 10, 2023

From Arcutis Biotherapeutics, Inc.

Via GlobeNewswire

Arcutis Announces Second Quarter 2023 Financial Results and Provides Business Update

August 08, 2023

From Arcutis Biotherapeutics, Inc.

Via GlobeNewswire

Arcutis to Report Second Quarter Financial Results

July 24, 2023

From Arcutis Biotherapeutics, Inc.

Via GlobeNewswire

Arcutis Announces ZORYVE® (Roflumilast) Cream 0.3% Has Been Included in a Preferred Position on National Formularies for CVS Caremark

July 17, 2023

From Arcutis Biotherapeutics, Inc.

Via GlobeNewswire

Carnival, SMART Global, Friedman Industries And Other Big Stocks Moving Higher On Friday ↗

June 30, 2023

U.S. stocks traded higher, with the Dow Jones gaining more than 200 points on Friday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Why Shares of Arcutis Biotherapeutics Jumped This Week ↗

June 09, 2023

The stock got a push when a British medical journal posted trials information on the company's lead product.

Via The Motley Fool

Arcutis to Present at Upcoming Investor Conference

June 06, 2023

From Arcutis Biotherapeutics, Inc.

Via GlobeNewswire

7 Short-Interest Stocks to Target for Explosive Gains ↗

May 18, 2023

For contrarian investors that can stand the heat, short-interest stocks to buy can offer significant rewards in a short time period.

Via InvestorPlace

10 Health Care Stocks With Whale Alerts In Today's Session ↗

May 18, 2023

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

May 10, 2023

Via Benzinga

Arcutis Announces First Quarter 2023 Financial Results and Provides Business Update

May 09, 2023

From Arcutis Biotherapeutics, Inc.

Via GlobeNewswire

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.